Document 0791
 DOCN  M9460791
 TI    Changes in the dominant Epstein-Barr virus type during human
       immunodeficiency virus infection.
 DT    9404
 AU    Buisson M; Morand P; Genoulaz O; Bourgeat MJ; Micoud M; Seigneurin JM;
       Laboratoire de Virologie, Faculte de Medecine-CHU, Grenoble,; France.
 SO    J Gen Virol. 1994 Feb;75 ( Pt 2):431-7. Unique Identifier : AIDSLINE
       MED/94157503
 AB    Two types of Epstein-Barr virus (EBV), EBV-1 and EBV-2, were identified
       on the basis of DNA sequence divergence in the genes for nuclear
       proteins EBNA 2, 3a, 3b and 3c. In the present study, we conducted an
       immunological and genomic analysis in a human immunodeficiency virus
       (HIV)-infected population to determine the prevalence of the two types,
       and whether the identified type was stable over years. The EBNA-2
       serotyping and genotyping showed that HIV-infected patients were highly
       infected by EBV-2, and that the dominant strain was mostly retained.
       However, during a follow-up study, a change in the dominant viral strain
       was observed in two patients. A first HIV-positive patient (patient A),
       although having a stable level of anti-EBNA-2A and -2B antibodies,
       showed a change in the genotype and antigen produced in spontaneously
       established lymphoblastoid cell lines (LCL). The sequence analysis of
       LCLs confirmed the emergence of the EBV-2 type population. A strain from
       a second HIV-positive patient (patient B) was clearly identified as
       EBV-2: the genotype from a saliva sample and from sequential LCLs
       belonged to EBV-2, as well as the antigen produced from LCLs, and serum
       antibodies. After a 5-year continuous EBV-2 infection, a reactivation of
       the EBV-1 strain was observed. In both cases, sequence analysis of the
       EBNA-2 gene showed, only with EBV-1, the presence of EBV variants
       related to the B95-8 prototype. Two mutations (at nucleotides 49212 and
       49304) were found in both patients A and B, whereas an additional
       mutation (at nucleotide 49237) was characteristic of the patient A. No
       mutation relative to the prototype B95-8 strain was observed in a
       subsequent analysis of this EBNA-2 region from LCLs obtained from two
       HIV-negative patients predominantly infected by EBV-1. Therefore, we
       speculate that these mutations may be EBV-1 mutations specifically
       occurring during HIV infection.
 DE    Antigens, Viral/GENETICS/IMMUNOLOGY  Base Sequence  DNA-Binding
       Proteins/GENETICS/IMMUNOLOGY  DNA, Viral/ANALYSIS  Herpesvirus 4,
       Human/*CLASSIFICATION/GENETICS/IMMUNOLOGY  Human  HIV
       Infections/*MICROBIOLOGY  Molecular Sequence Data  Mutation  Polymerase
       Chain Reaction  Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).